N. Fischbach

发表

A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer

J. Lacy, J. Kortmansky, H. Hochster, 2020, Cancer.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study

T. Lynch, A. Wozniak, Priya Kumar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2021, NPJ breast cancer.

Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS)

T. Lynch, Priya Kumar, S. Teng, 2008 .

A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

J. Lacy, J. Kortmansky, H. Hochster, 2019, Journal of Clinical Oncology.

Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).

R. Salem, J. Lacy, J. Kortmansky, 2015 .

Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy

L. Harris, V. Bossuyt, D. Tuck, 2013, PloS one.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

J. Berk-Krauss, M. Sznol, M. Tomayko, 2018, Journal of the American Academy of Dermatology.

[One-stage surgery of high trans- and supra-sphincter anal fistula using primary fistulectomy and occlusion of the internal fistula ostium. A prospective study of 169 patients].

B. Meyer, N. Fischbach, S. Athanasiadis, 1991, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).

R. Salem, J. Lacy, B. Chang, 2014 .

Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma

J. Lacy, J. Kortmansky, H. Hochster, 2017, American journal of clinical oncology.

Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).

R. Robles, T. Lynch, D. Spigel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.

L. Pusztai, T. Qing, D. Rimm, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

L. Pusztai, T. Qing, D. Rimm, 2021, npj Breast Cancer.

[Abscess excision and primary fistulectomy as initial therapy of peri-proctal abscess. A prospective analysis of 122 patients].

N. Fischbach, S. Athanasiadis, B. Marla, 1990, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.